Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 2/20 | 0.56 |
| ▸ | MAOB | P27338 | 9/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | P4HB | P07237 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167413 | 1.00 | NFKB1 (0.56) | NFKB1MAOBCA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL6821159 | 0.98 | NFKB1 (0.54) | NFKB1MAOBCA1CA2CA4 | |
| SCHEMBL6821155 | 0.85 | NFKB1 (0.54) | NFKB1MAOBP4HBABCG2MAOA | |
| SCHEMBL6821153 | 0.85 | NFKB1 (0.54) | NFKB1MAOBP4HBABCG2MAOA | |
| SCHEMBL1167281 | 0.85 | MIF (0.47) | NFKB1MAOBCA1CA2CA4 | |
| SCHEMBL1167283 | 0.85 | MIF (0.47) | NFKB1MAOBCA1CA2CA4 | |
| SCHEMBL8055837 | 0.84 | NFKB1 (0.77) | NFKB1MAOBCA1CA2CA4 | |
| SCHEMBL29365331 | 0.84 | NFKB1 (0.77) | NFKB1MAOBCA1CA2CA4 | |
| SCHEMBL82267 | 0.84 | NFKB1 (0.77) | NFKB1MAOBCA1CA2CA4 | |
| SCHEMBL82266 | 0.84 | NFKB1 (0.77) | NFKB1MAOBCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242743-B1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-8288419-B2 | Aminopyrazole derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2012-10-16 | — | — | US | disclosed |
| EP-2421856-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | disclosed |
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION (CH) | 2011-02-10 | — | — | US | disclosed |
| WO-2010124112-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| EP-2242743-A1 | AMINOPYRAZOLE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009077954-A1 | AMINOPYRAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2004046122-A2 | BENZOXAZOLE, BENZTHIAZOLE AND BENZIMIDAZOLE ACID DERIVATIVES AND THEIR USE AS HEPARANASE INHIBITORS | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2004-06-03 | — | — | WO | disclosed |
| JP-2004149458-A | METHOD FOR PRODUCING FLUORO(TRIFLUOROMETHYL)CINNAMIC ACID | CENTRAL GLASS CO LTD | 2004-05-27 | — | — | JP | disclosed |
| WO-2004039760-A1 | PROCESS FOR PRODUCTION OF FLUORO(TRIFLUOROMETHYL)- CINNAMIC ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034516-A1 | AMINOPYRAZOLE DERIVATIVES | CYP3A43, CYP1A2, CYP3A5 | NFKB1 2598/4885MAOB 253/4885CA1 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.